Allogene Therapeutics Inc logo

ALLO - Allogene Therapeutics Inc Share Price

$29.58 -3.2  -9.9%

Last Trade - 9:00pm

Large Cap
Market Cap £3.37bn
Enterprise Value £2.76bn
Revenue £n/a
Position in Universe 1470th / 6825
Unlock ALLO Revenue
Relative Strength (%)
1m -17.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -40.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 12.4
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AllogeneTherapeutics Inc revenues was not reported. Net lossincreased 36% to $250.2M. Higher net loss reflects Researchand Development increase of 34% to $161.7M (expense),Stock-based Compensation in R&D increase of 61% to $31.3M(expense), Interest and other income, net decrease of 47%to $9.2M (income). Basic Earnings per Share excludingExtraordinary Items decreased from -$1.83 to -$2.08.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ALLO
Graphical History


ALLO Revenue Unlock ALLO Revenue

Net Income

ALLO Net Income Unlock ALLO Revenue

Normalised EPS

ALLO Normalised EPS Unlock ALLO Revenue

PE Ratio Range

ALLO PE Ratio Range Unlock ALLO Revenue

Dividend Yield Range

ALLO Dividend Yield Range Unlock ALLO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALLO EPS Forecasts Unlock ALLO Revenue
Profile Summary

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated November 30, 2017
Public Since October 11, 2018
No. of Shareholders: 69
No. of Employees: 265
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 140,647,818
Free Float (0.0%)
Eligible for
ALLO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ALLO
Upcoming Events for ALLO
Tuesday 4th May, 2021 Estimate
Q1 2021 Allogene Therapeutics Inc Earnings Release
Friday 4th June, 2021 Estimate
Allogene Therapeutics Inc Annual Shareholders Meeting
Tuesday 3rd August, 2021 Estimate
Q2 2021 Allogene Therapeutics Inc Earnings Release
Frequently Asked Questions for Allogene Therapeutics Inc
What is the Allogene Therapeutics Inc share price?

As of 9:00pm, shares in Allogene Therapeutics Inc are trading at $29.58, giving the company a market capitalisation of £3.37bn. This share price information is delayed by 15 minutes.

How has the Allogene Therapeutics Inc share price performed this year?

Shares in Allogene Therapeutics Inc are currently trading at $29.58 and the price has moved by 44.65% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allogene Therapeutics Inc price has moved by -2.5% over the past year.

What are the analyst and broker recommendations for Allogene Therapeutics Inc?

Of the analysts with advisory recommendations for Allogene Therapeutics Inc, there are there are currently 7 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Allogene Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Allogene Therapeutics Inc next release its financial results?

Allogene Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Allogene Therapeutics Inc dividend yield?

Allogene Therapeutics Inc does not currently pay a dividend.

Does Allogene Therapeutics Inc pay a dividend?

Allogene Therapeutics Inc does not currently pay a dividend.

When does Allogene Therapeutics Inc next pay dividends?

Allogene Therapeutics Inc does not currently pay a dividend.

How do I buy Allogene Therapeutics Inc shares?

To buy shares in Allogene Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Allogene Therapeutics Inc?

Shares in Allogene Therapeutics Inc are currently trading at $29.58, giving the company a market capitalisation of £3.37bn.

Where are Allogene Therapeutics Inc shares listed? Where are Allogene Therapeutics Inc shares listed?

Here are the trading details for Allogene Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALLO
What kind of share is Allogene Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Allogene Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Allogene Therapeutics Inc share price forecast 2021?

Shares in Allogene Therapeutics Inc are currently priced at $29.58. At that level they are trading at 54.24% discount to the analyst consensus target price of 0.00.

Analysts covering Allogene Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.186 for the next financial year.

How can I tell whether the Allogene Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allogene Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -31.85%. At the current price of $29.58, shares in Allogene Therapeutics Inc are trading at -5.87% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Allogene Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Allogene Therapeutics Inc.

Who are the key directors of Allogene Therapeutics Inc?

Allogene Therapeutics Inc's management team is headed by:

Arie Belldegrun - CHM
David Chang - PRE
Alison Moore - CTO
Eric Schmidt - CFO
David Bonderman - LED
John DeYoung - IND
Franz Humer - IND
Joshua Kazam - CFD
Deborah Messemer - IND
Todd Sisitsky - IND
Rafael Amado - EVP
Veer Bhavnagri - CCO
Who are the major shareholders of Allogene Therapeutics Inc?

Here are the top five shareholders of Allogene Therapeutics Inc based on the size of their shareholding:

Pfizer Inc Corporation
Percentage owned: 15.66% (22.0m shares)
TPG Capital, L.P. Private Equity
Percentage owned: 13.31% (18.7m shares)
American Funds Growth Fund of America Mutual Fund
Percentage owned: 9.41% (13.2m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 8.99% (12.6m shares)
Gilead Sciences Inc Corporation
Percentage owned: 5.32% (7.49m shares)
Similar to ALLO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.